EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling at least 1,000 schizophrenia patients with topline results expected in Q4-2026
Share This Blog
Ready-to-post copy includes the blog link.
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling at le... Read the full IIPLA blog post: https://iipla.org/blog/newron-further-expands-intellectual-property-portfolio-for-evenamide-with-new-eu-composition-of-matter-patent